CARDIO DIAGNOSTICS HOLDINGS (CDIO)
US14159C1036 - Common Stock
Overall CDIO gets a fundamental rating of 1 out of 10. We evaluated CDIO against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of CDIO have multiple concerns. CDIO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
CDIO had negative earnings in the past year.
In the past year CDIO has reported a negative cash flow from operations.
1.2 Ratios
With a Return On Assets value of -187.54%, CDIO is not doing good in the industry: 88.91% of the companies in the same industry are doing better.
CDIO has a Return On Equity of -282.91%. This is in the lower half of the industry: CDIO underperforms 73.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -187.54% | ||
| ROE | -282.91% | ||
| ROIC | N/A |
ROA(3y)-106.21%
ROA(5y)N/A
ROE(3y)-149.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CDIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CDIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDIO has more shares outstanding than it did 1 year ago.
CDIO has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -3.44, we must say that CDIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CDIO (-3.44) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.13 indicates that CDIO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.13, CDIO is doing worse than 64.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.44 |
ROIC/WACCN/A
WACC9.06%
2.3 Liquidity
CDIO has a Current Ratio of 3.29. This indicates that CDIO is financially healthy and has no problem in meeting its short term obligations.
CDIO has a worse Current ratio (3.29) than 63.65% of its industry peers.
A Quick Ratio of 3.29 indicates that CDIO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.29, CDIO is doing worse than 62.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.29 |
3. Growth
3.1 Past
The earnings per share for CDIO have decreased strongly by -49.60% in the last year.
EPS 1Y (TTM)-49.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -16.62% on average over the next years. This is quite bad
CDIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 467.90% yearly.
EPS Next Y1.09%
EPS Next 2Y-16.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1978.58%
Revenue Next 2Y817.87%
Revenue Next 3Y467.9%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CDIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CDIO's earnings are expected to decrease with -16.62% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.62%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CDIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CARDIO DIAGNOSTICS HOLDINGS
NASDAQ:CDIO (4/30/2024, 7:00:02 PM)
Premarket: 0.661 -0.02 (-3.5%)0.685
-0.01 (-2.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.79M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -187.54% | ||
| ROE | -282.91% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-49.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y1.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y